Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
YMN-A03
- Development stage
- Unknown
- Lead developer
- West China Hospital of Sichuan University
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Inhalation
01
Overview
YMN-A03 is a novel, nebulized bifunctional fusion protein consisting of a nanobody (VHH) targeting programmed cell death 1 ligand 1 (PD-L1) fused to interleukin-15 (IL-15). Developed by West China Hospital of Sichuan University, it is designed for local delivery to the lungs via inhalation to treat advanced non-small cell lung cancer (NSCLC). By targeting PD-L1, YMN-A03 blocks the PD-1/PD-L1 checkpoint pathway, while the IL-15 component promotes the activation and proliferation of T cells and natural killer (NK) cells within the tumor microenvironment. The nebulized formulation aims to achieve high local concentrations in the lung while minimizing systemic toxicity. It is currently being evaluated in Phase I clinical trials for patients with advanced NSCLC who have progressed after standard systemic therapies.
- Other names
- YMN-A03YMN-A-03YMN-A 03
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)
Beyond the preview
Go deeper on YMN-A03.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on YMN-A03.